NCT00878072View on ClinicalTrials.gov

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

March 25, 2009

Primary Completion Date

June 2, 2010

Study Completion Date

June 2, 2010

Conditions
Herpes Labialis
Interventions
DRUG

Famciclovir

Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.

Trial Locations (12)

44106

University Hospitals Case Medical Center, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

47714

Medisphere Medical Research Center, LLC, Evansville

60614

Children's Memorial Hospital, Chicago

63117

Clayton Medical Research, St Louis

77030

Texas Children's Hospital, Houston

77566

R/D Clinical Research, Inc, Lake Jackson

R/D Clinical Research, Lake Jackson

97210

Westover Heights Clinic, Portland

Unknown

Women's Health Care at Frost Street, San Diego

Rochester Clinical Research, Inc., Rochester

Primary Physicians Research, Inc, Pittsburgh

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY